Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.73 |
| ▸ | ABL1 | P00519 | 4/20 | 0.73 |
| ▸ | HCK | P08631 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CSK | P41240 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.53 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.53 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 4/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19375751 | 0.88 | SRC (0.73) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL19375771 | 0.87 | SRC (0.65) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL12437021 | 0.84 | SRC (1.00) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL29387843 | 0.84 | SRC (1.00) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL12435985 | 0.83 | SRC (0.75) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL29390235 | 0.83 | SRC (0.75) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL12435986 | 0.82 | SRC (0.77) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL29390285 | 0.82 | SRC (0.77) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL22224606 | 0.80 | SRC (0.71) | SRCABL1HCKRIPK2PRKD3 | |
| SCHEMBL12436152 | 0.80 | SRC (1.00) | SRCABL1HCKRIPK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | University of Washington Through its Center for Co (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-9765037-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885HCK 9/4885 |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885HCK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.